Page last updated: 2024-08-22

deuterium and ly 518674

deuterium has been researched along with ly 518674 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bloedon, LT; Duffy, D; Dunbar, RL; Fuki, IV; Gadi, R; Harris, CJ; Howey, DC; McCoy, M; Millar, JS; Movva, R; Rader, DJ; Shah, A; Wang, MD; Wolfe, ML	1

Trials

1 trial(s) available for deuterium and ly 518674

Article	Year
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Deuterium; Double-Blind Method; Female; Humans; Kinetics; Male; Metabolic Syndrome; Middle Aged; Placebos; PPAR alpha; Propionates; Triazoles; Triglycerides; Young Adult	2009

Article

Year

Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.

Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:1

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Deuterium; Double-Blind Method; Female; Humans; Kinetics; Male; Metabolic Syndrome; Middle Aged; Placebos; PPAR alpha; Propionates; Triazoles; Triglycerides; Young Adult

2009